RayKnowChina Research Map
Shortlist0

RecruitingMultiple myelomaPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

An open trial on multiple myeloma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Soochow University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04025450, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. RISS-3;

    Inclusion criterion 3

    8.Normal left ventricular ejaculation rate, NYHA stage 1, pulmonary function GOLD stage 1;

    Inclusion criterion 16

  3. 2.Having received any of the medicine of the experiment regimen within 30 days prior to enrollment, pain-relieving radiotherapy is allowed;

    Exclusion criterion 2

  4. 4.ECOG 0-2 points, with life expectance ≥3 months; GA score <2;

    Inclusion criterion 12

  5. 5.ALT/AST level <2.5 times of the maximum of normal range; total bilirubin<1.5 times of normal maximum;

    Inclusion criterion 13

    6.Neutrophil count≥1.5×109/L, platelet count≥50×109/L;

    Inclusion criterion 14

    7.eGFR≥40ml/min,except in the case of myeloma-related nephropathy;

    Inclusion criterion 15

  6. 2.Secretory MM should have measurable markers, including:

    Inclusion criterion 7

    and/or measurable extramedullary foci (diameter>1cm on CT);

    Inclusion criterion 10

  7. 9.With active hepatitis;

    Exclusion criterion 9

    10.HIV positive;

    Exclusion criterion 10

    11.History of other malignant tumor within 5 years prior to enrollment; except for the case of in situ cervical cancer and non-malignant melanoma;

    Exclusion criterion 11

  8. 4.Patients in pregnancy or lactation;

    Exclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04025450, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1.Diagnosed as multiple myeloma, and has one of the above:
  • high risk karyotype, such as 17p-,t(4;14),t(14;16),t(14;20)或1q gain,1p-, double hit myeloma, triple hit myeloma, etc;
  • RISS-3;
  • IgD/IgE MM;
  • with measurable extra-medullary plasmacytoma;
  • flowcytometry showed peripheral blood plasma cell ≥0.165%;
  • 2.Secretory MM should have measurable markers, including:
  • specific M protein value (≥5g/L);
  • and/or involved flc ≥100mg/L;
  • and/or measurable extramedullary foci (diameter>1cm on CT);
  • 3.Age≥18 years, male or female;
  • 4.ECOG 0-2 points, with life expectance ≥3 months; GA score <2;
  • 5.ALT/AST level <2.5 times of the maximum of normal range; total bilirubin<1.5 times of normal maximum;
  • 6.Neutrophil count≥1.5×109/L, platelet count≥50×109/L;
  • 7.eGFR≥40ml/min,except in the case of myeloma-related nephropathy;
  • 8.Normal left ventricular ejaculation rate, NYHA stage 1, pulmonary function GOLD stage 1;
  • 9.Willing to accept the possibility of potential adverse events and efficacy observation by the investigators;
  • 10.Being able to understand and signing the written consent, which should be signed prior to any procedure of the trial.

Exclusion Criteria:

  • 1.With ≥2 degree of peripheral neuropath or with pain;
  • 2.Having received any of the medicine of the experiment regimen within 30 days prior to enrollment, pain-relieving radiotherapy is allowed;
  • 3.With severe pulmonary/cardiac disfunction (including history of QT interval elongation, ventricular tachycardia, ventricular fibrillation, myocardial infraction) or other severe organ malfunction;
  • 4.Patients in pregnancy or lactation;
  • 5.Allergic constitution or being allergic to any drug within the regimen of the trial;
  • 6.With uncontrolled mental diseases;
  • 7.With active infection;
  • 8.With non-myeloma-associated acute renal dysfunction;
  • 9.With active hepatitis;
  • 10.HIV positive;
  • 11.History of other malignant tumor within 5 years prior to enrollment; except for the case of in situ cervical cancer and non-malignant melanoma;
  • 12.With other conditions that the investigators think unfit for the trial.

Quoted from ClinicalTrials.gov, NCT04025450, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04025450, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04025450